The Synergism Or Long Duration (SOLD) Study (SOLD)

Clinical Trial ID NCT00593697

Rank	Title	Journal	Year	PubWeight™‹?›
1	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nat Rev Clin Oncol	2011	4.12
2	Treatment of HER2-positive breast cancer.	Breast	2013	1.09
3	The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.	Curr Oncol	2009	0.98
4	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.	BMC Cancer	2014	0.93
5	Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.	Br J Cancer	2010	0.88
6	Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.	Breast Cancer Res Treat	2015	0.80
7	Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.	Chemother Res Pract	2011	0.79
8	Treatment of early-stage HER2+ breast cancer-an evolving field.	Ecancermedicalscience	2015	0.79
9	Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.	Target Oncol	2016	0.75
10	Adjuvant trastuzumab: does time really matter?	Oncologist	2013	0.75
11	Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.	PLoS Med	2016	0.75